Has a HCC diagnosis confirmed by radiology, histology, or cytology (fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible) 
Has Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach 
Has a Child-Pugh A liver score within 7 days prior to first dose of study medication 
Has a life expectancy of >3 months 
Has at least one measurable lesion based on RECIST version 1.1 as determined by investigator 
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 7 days prior to receiving the first dose of study medication 
Has documented objective radiographic progression during or after treatment with sorafenib or oxaliplatin-based chemotherapy, or else intolerance to sorafenib or oxaliplatin-based chemotherapy 
Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy 
Female and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medication 

NCT03062358_inc_T1
Condition
HCC
NCT03062358_inc_T2
Procedure
radiology
NCT03062358_inc_T3
Procedure
histology
NCT03062358_inc_T4
Procedure
cytology
NCT03062358_inc_T5
Scope
radiology, histology, or cytology
NCT03062358_inc_T6
Condition
subtype fibrolamellar
NCT03062358_inc_T7
Condition
mixed hepatocellular/cholangiocarcinoma subtype
NCT03062358_inc_T8
Negation
not eligible
NCT03062358_inc_T9
Scope
fibrolamellar, and mixed hepatocellular/cholangiocarcinoma subtypes are not eligible
NCT03062358_inc_T10
Measurement
Barcelona Clinic Liver Cancer (BCLC)
NCT03062358_inc_T11
Value
Stage C
NCT03062358_inc_T12
Condition
disease
NCT03062358_inc_T14
Measurement
BCLC
NCT03062358_inc_T15
Value
Stage B
NCT03062358_inc_T16
Qualifier
amenable to locoregional therapy
NCT03062358_inc_T17
Qualifier
refractory to locoregional therapy
NCT03062358_inc_T18
Qualifier
amenable to a curative treatment approach
NCT03062358_inc_T19
Negation
not
NCT03062358_inc_T20
Negation
not
NCT03062358_inc_T21
Scope
amenable to locoregional therapy or refractory to locoregional therapy
NCT03062358_inc_T22
Condition
disease
NCT03062358_inc_T24
Measurement
Child-Pugh liver score
NCT03062358_inc_T25
Value
A
NCT03062358_inc_T26
Temporal
within 7 days prior
NCT03062358_inc_T27
Reference_point
first dose of study medication
NCT03062358_inc_T28
Observation
life expectancy
NCT03062358_inc_T29
Value
>3 months
NCT03062358_inc_T30
Multiplier
at least one
NCT03062358_inc_T32
Condition
lesion
NCT03062358_inc_T31
Measurement
RECIST version 1.1
NCT03062358_inc_T33
Value
measurable
NCT03062358_inc_T34
Measurement
Eastern Cooperative Oncology Group (ECOG) performance status
NCT03062358_inc_T35
Value
0 or 1
NCT03062358_inc_T36
Temporal
within 7 days prior
NCT03062358_inc_T37
Reference_point
receiving the first dose of study medication
NCT03062358_inc_T38
Procedure
radiographic
NCT03062358_inc_T39
Observation
objective progression
NCT03062358_inc_T40
Temporal
during or after
NCT03062358_inc_T41
Reference_point
treatment with sorafenib or oxaliplatin-based chemotherapy
NCT03062358_inc_T42
Drug
sorafenib
NCT03062358_inc_T43
Drug
oxaliplatin
NCT03062358_inc_T44
Qualifier
sorafenib or oxaliplatin-based
NCT03062358_inc_T45
Procedure
chemotherapy
NCT03062358_inc_T46
Condition
intolerance
NCT03062358_inc_T47
Drug
sorafenib
NCT03062358_inc_T48
Drug
oxaliplatin
NCT03062358_inc_T49
Qualifier
sorafenib or oxaliplatin-based
NCT03062358_inc_T50
Procedure
chemotherapy
NCT03062358_inc_T51
Person
Female
NCT03062358_inc_T52
Condition
childbearing potential
NCT03062358_inc_T53
Scope
Female participants of childbearing potential
NCT03062358_inc_T54
Measurement
pregnancy test urine
NCT03062358_inc_T55
Measurement
serum pregnancy test
NCT03062358_inc_T56
Temporal
within 72 hours prior
NCT03062358_inc_T57
Scope
urine or serum pregnancy test
NCT03062358_inc_T58
Value
negative
NCT03062358_inc_T59
Reference_point
receiving the first dose of study therapy
NCT03062358_inc_T60
Procedure
adequate contraception
NCT03062358_inc_T61
Person
male
NCT03062358_inc_T62
Person
Female
NCT03062358_inc_T64
Condition
reproductive potential
NCT03062358_inc_T65
Scope
Female and male participants of reproductive potential